Dividend 15 Split Corp. Monthly Dividend Declaration for Class A & Preferred Share

TORONTO, Jan. 20, 2025 (GLOBE NEWSWIRE) — Dividend 15 Split Corp. (The “Company”) declares its monthly distribution of $0.10000 for each Class A share ($1.20 annualized) and $0.05833 for each Preferred share ($0.700 annually). Distributions are payable February 10, 2025 to shareholders on record as at January 31, 2025.

Since inception Class A shareholders have received a total of $27.60 per share and Preferred shareholders have received a total of $11.11 per share inclusive of this distribution, for a combined total of $38.71.

Dividend 15 invests in a high quality portfolio of leading Canadian dividend-yielding stocks as follows: Bank of Montreal, Bank of Nova Scotia, Canadian Imperial Bank of Commerce, Royal Bank of Canada, Toronto-Dominion Bank, National Bank of Canada, CI Financial Corp., BCE Inc., Manulife Financial, Enbridge, Sun Life Financial, TELUS Corporation, Thomson Reuters Corporation, TransAlta Corporation, TC Energy Corporation.

Distribution Details

Class A Share (DFN)	$0.10000
Preferred Share (DFN.PR.A)	$0.05833
Record Date:	January 31, 2025
Payable Date:	February 10, 2025

Investor Relations: 1-877-478-2372
Local: 416-304-4443
www.dividend15.com
[email protected]

Dividend 15 Split Corp. Monthly Dividend Declaration for Class A & Preferred Share

Vallourec reduces its carbon footprint by 19% in 4 years

Transaction in Own Shares

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Patrik Hammarén appointed as President of Nokia Technologies

Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care

Topics

Vallourec reduces its carbon footprint by 19% in 4 years

Transaction in Own Shares

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Patrik Hammarén appointed as President of Nokia Technologies

Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care

Belships ASA: Update on pre-acceptances

Nasdaq Report Identifies Between $25 Billion and $50 Billion in Potential Efficiency Gains in Banks’ Risk and Compliance Functions

Enact Receives Ratings Upgrades from Fitch Ratings

Related Articles

Vallourec reduces its carbon footprint by 19% in 4 years

Transaction in Own Shares

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Patrik Hammarén appointed as President of Nokia Technologies

Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care

Company

Headlines

Vallourec reduces its carbon footprint by 19% in 4 years

Transaction in Own Shares

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Patrik Hammarén appointed as President of Nokia Technologies

Newsletter